|Ms. Judith Greciet||CEO & Director||455.5k||N/A||1968|
|Mr. Nicolas Fellmann||CFO & Admin. and Fin. Director||N/A||N/A||1968|
|Dr. FranÃ§oise Bono Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Audrey Legentil-Dumery||Director of HR||N/A||N/A||N/A|
|Mr. Michel Forest||Chief Pharmacist & Quality Assurance Director||N/A||N/A||N/A|
|Mr. Philippe M. Maitre||Chief of US Operations & Exec. VP||N/A||N/A||1957|
|Dr. Olivier de Beaumont M.D., MBA||Chief Medical Officer||N/A||N/A||N/A|
Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.
Onxeo SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.